HYPERGENES
"European Network for Genetic-Epidemiological Studies: building a method to dissect complex genetic traits, using essential hypertension as a disease model"
| Coordinatore | UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 14˙608˙340 € |
| EC contributo | 10˙213˙420 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-IP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-01-01 - 2011-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
IT (MILANO) | coordinator | 0.00 |
| 2 |
"Institute of Internal Medicine, Siberian Branch of the Russian Academy of Medical Sciences"
Organization address
address: St. B. Bogatkova 175/5 contact info |
RU (Novosibirsk) | participant | 0.00 |
| 3 |
"REFORM E.C., DRUZBA ZA MEDNARODNO TRGOVINO, D.O.O."
Organization address
address: Kidriceva Ulica 20 contact info |
SI (Nova Gorica) | participant | 0.00 |
| 4 |
GDANSKI UNIWERSYTET MEDYCZNY
Organization address
address: ULICA M SKLODOWSKIEJ CURIE 3A contact info |
PL (GDANSK) | participant | 0.00 |
| 5 |
I.M.S. - Istituto di Management Sanitario S.r.l.
Organization address
address: Via Podgora 7 contact info |
IT (Milan) | participant | 0.00 |
| 6 |
IBM ISRAEL - SCIENCE AND TECHNOLOGY LTD
Organization address
address: 94 DERECH EM-HAMOSHAVOT contact info |
IL (PETACH TIKVA) | participant | 0.00 |
| 7 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 0.00 |
| 8 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 0.00 |
| 9 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 0.00 |
| 10 |
Pharnext S.A.S.
Organization address
city: Paris contact info |
FR (Paris) | participant | 0.00 |
| 11 |
Shanghai Institute of Hypertension
Organization address
address: Ruijin 2nd Road 197 contact info |
CN (Shanghai) | participant | 0.00 |
| 12 |
SOFTECO SISMAT SRL
Organization address
address: VIA DE MARINI 1 contact info |
IT (GENOVA) | participant | 0.00 |
| 13 |
STMICROELECTRONICS SRL
Organization address
address: VIA C.OLIVETTI 2 contact info |
IT (AGRATE BRIANZA) | participant | 0.00 |
| 14 |
THE UNIVERSITY OF WARWICK
Organization address
address: Kirby Corner Road - University House - contact info |
UK (COVENTRY) | participant | 0.00 |
| 15 |
UNIVERSITA DEGLI STUDI DI PADOVA
Organization address
address: VIA 8 FEBBRAIO 2 contact info |
IT (PADOVA) | participant | 0.00 |
| 16 |
UNIVERSITA DEGLI STUDI DI SASSARI
Organization address
address: PIAZZA UNIVERSITA 21 contact info |
IT (SASSARI) | participant | 0.00 |
| 17 |
UNIVERSITE DE LAUSANNE
Organization address
city: LAUSANNE contact info |
CH (LAUSANNE) | participant | 0.00 |
| 18 |
UNIVERZITA KARLOVA V PRAZE
Organization address
address: Ovocny trh 5 contact info |
CZ (PRAHA 1) | participant | 0.00 |
| 19 |
UNIWERSYTET JAGIELLONSKI
Organization address
address: Ul. Golebia 24 contact info |
PL (KRAKOW) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The project is focused on the definition of a comprehensive genetic epidemiological model of complex traits like Essential Hypertension (EH) and intermediate phenotypes of hypertension dependent/associated Target Organ Damages (TOD). To identify the common genetic variants relevant for the pathogenesis of EH and TODs, we will perform a Whole Genome Association (WGA) study of 4.000 subjects recruited from historical well-characterized European cohorts. Genotyping will be done with the Illumina Human 1M BeadChip. Well-established multi-variate techniques and innovative genomic analyses through machine learning techniques will be used for the WGA investigations. Using machine learning approach we aim at developing a disease model of EH integrating the available information on EH and TOD with relevant validated pathways and genetic/environmental information to mimic the clinician's recognition pattern of EH/TOD and their causes in an individual patient. Our statistical design is with two samples run in parallel, each with 1,000 cases and 1,000 controls, followed by a replication/joint analysis. This design is more powerful than replication alone and allows also a formal testing of the potential heterogeneity of findings compared to a single step (one large sample) design. The results represent the source to build a customized and inexpensive genetic diagnostic chip that can be validated in our existing cohorts (n=12,000 subjects). HYPERGENES is in the unique position to propose a ground-breaking project, improving the methodology of genetic epidemiology of chronic complex diseases that have a high prevalence among EU populations. Designing a comprehensive genetic epidemiological model of complex traits will also help us to translate genetic findings into improved diagnostic accuracy and new strategies for early detection, prevention and eventually personalised treatment of a complex trait. The ultimate goal will be to promote the quality of life of EU populations.'
Introduzione (Teaser)
A complex trait is phenotypically and genetically heterogeneous and thus requires a global genomic approach to understand its aetiology and pathogenesis. To this end, EU-funded researchers joined forces to disentangle the genetic bases of a complex disease using population genetic epidemiology.
Altri progetti dello stesso programma (FP7-HEALTH)
LOULLA&PHILLA (2008)
Development of 6-mercaptopurine and Methotrexate oral liquid formulations for the maintenance treatment of Acute Lymphoblastic Leukæmia in children
Read MoreREQUITE (2013)
Validating predictive models of radiotherapy toxicity to improve quality-of-life and reduce side-effects in cancer survivors
Read More